Granted Patent
B2
US 12,576,065 · App. 19/170,770 · Granted Mar 17, 2026
Enhancing autophagy or increasing longevity by administration of urolithins
Inventors:
Christopher L. Rinsch (Lausanne, CH); William Blanco-Bose (La Croix, CH); Bernard Schneider (Pully, CH); Laurent Mouchiroud (Morges, CH); Dongryeol Ryu (Renens, CH); Penelope Andreux (Eclepens, CH); Johan Auwerx (Buchillon, CH)
Assignee:
Amazentis SA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
Claims (16)
1 . A composition comprising urolithin A, or a pharmaceutically acceptable salt thereof; and spermidine.
2 . The composition of claim 1 , wherein the composition further comprises an acceptable carrier.
3 . The composition of claim 1 , wherein the composition is in the form of a dietary supplement.
4 . The composition of claim 2 , wherein the composition is in the form of a dietary supplement.
5 . The composition of claim 1 , wherein the composition is in the form of a nutraceutical.
6 . The composition of claim 2 , wherein the composition is in the form of a nutraceutical.
7 . The composition of claim 1 , wherein the composition is in the form of a food additive.
8 . The composition of claim 2 , wherein the composition is in the form of a food additive.
9 . The composition of claim 1 , wherein the composition is in the form of a functional food.
10 . The composition of claim 2 , wherein the composition is in the form of a functional food.
11 . The composition of claim 1 , wherein the composition is formulated for oral administration.
12 . The composition of claim 2 , wherein the composition is formulated for oral administration.
13 . The composition of claim 1 , wherein the composition is formulated for topical administration.
14 . The composition of claim 2 , wherein the composition is formulated for topical administration.
15 . The composition of claim 1 , wherein the composition is formulated for buccal administration.
16 . The composition of claim 2 , wherein the composition is formulated for buccal administration.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 19, 2025
From: RINSCH, CHRISTOPHER L.; BLANCO-BOSE, WILLIAM
To: AMAZENTIS SA
Reel/Frame 073970/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 19, 2025
From: SCHNEIDER, BERNARD; AUWERX, JOHAN; MOUCHIROUD, LAURENT; RYU, DONGRYEOL; ANDREUX, PENELOPE
To: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Reel/Frame 073276/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 19, 2025
From: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
To: AMAZENTIS SA
Reel/Frame 073971/0011 →
Continuity (7)
Provisional Application
61791137
· Mar 15, 2013
Provisional Application
61712886
· Oct 12, 2012
Provisional Application
61665137
· Jun 27, 2012
References Cited (294)
US 5073545A
· Arima et al.
· 1991
[cited by applicant]
US 6066312A
· Egawa et al.
· 2000
[cited by applicant]
US 6133311A
· Bok et al.
· 2000
[cited by applicant]
US 6440436B1
· Ghosal
· 2002
[cited by applicant]
US 8183282B2
· Seeram et al.
· 2012
[cited by applicant]
US 8894993B2
· Ghosal
· 2014
[cited by applicant]
US 8933217B2
· Rinsch et al.
· 2015
[cited by applicant]
US 9394269B2
· Rinsch et al.
· 2016
[cited by applicant]
US 9573922B2
· Rinsch et al.
· 2017
[cited by applicant]
US 9872850B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9962366B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9980980B2
· Rinsch et al.
· 2018
[cited by applicant]
US 9994542B2
· Rinsch et al.
· 2018
[cited by applicant]
US 20030078212A1
· Li et al.
· 2003
[cited by applicant]
US 20050282781A1
· Ghosal
· 2005
[cited by applicant]
US 20060257337A1
· Sherris
· 2006
[cited by applicant]
US 20080039179A1
· Seelig et al.
· 2008
[cited by applicant]
US 20100004334A1
· Jouni et al.
· 2010
[cited by applicant]
US 20100055247A1
· Tirrito
· 2010
[cited by applicant]
US 20100298249A1
· Moutet et al.
· 2010
[cited by applicant]
US 20110263521A1
· Moutet et al.
· 2011
[cited by applicant]
US 20160095881A1
· Sen
· 2016
[cited by applicant]
US 20180015069A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256471A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180256538A1
· Rinsch et al.
· 2018
[cited by applicant]
US 20180296464A1
· Graban et al.
· 2018
[cited by applicant]
US 20190000867A1
· Rinsch et al.
· 2019
[cited by applicant]
US 20200085895A1
· Patel et al.
· 2020
[cited by applicant]
US 20210210190A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210251869A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20210346342A1
· Rinsch et al.
· 2021
[cited by applicant]
US 20220280410A1
· Perretta et al.
· 2022
[cited by applicant]
US 20230277669A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230301890A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20230355501A1
· Ookura et al.
· 2023
[cited by applicant]
US 20230390238A1
· Rinsch et al.
· 2023
[cited by applicant]
US 20240148690A1
· Andreux et al.
· 2024
[cited by applicant]
US 20240156777A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20240366558A1
· Rinsch et al.
· 2024
[cited by applicant]
US 20250049750A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250161391A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250213524A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250228817A1
· Rinsch et al.
· 2025
[cited by applicant]
US 20250381118A1
· Rinsch et al.
· 2025
[cited by applicant]
CN 101301319A
· 2008
[cited by applicant]
CN 101484125A
· 2009
[cited by applicant]
CN 103442594A
· 2013
[cited by applicant]
CN 109316478A
· 2019
[cited by applicant]
CN 110368476A
· 2019
[cited by applicant]
CN 112843049A
· 2021
[cited by applicant]
CN 113171319A
· 2021
[cited by applicant]
CN 113476362A
· 2021
[cited by applicant]
CN 113855758A
· 2021
[cited by applicant]
CN 114794490A
· 2022
[cited by applicant]
CN 116889583A
· 2023
[cited by applicant]
EP 2033526A1
· 2009
[cited by applicant]
EP 2068864A2
· 2009
[cited by applicant]
JP H02304080A
· 1990
[cited by applicant]
JP 2008503456A
· 2008
[cited by applicant]
JP 2010280627A
· 2010
[cited by applicant]
JP 2016216378A
· 2016
[cited by applicant]
JP 2017007951A
· 2017
[cited by applicant]
JP 2017014154A
· 2017
[cited by applicant]
JP 2017019725A
· 2017
[cited by applicant]
JP 2017031108A
· 2017
[cited by applicant]
WO WO0006134A2
· 2000
[cited by applicant]
WO WO0015044A1
· 2000
[cited by applicant]
WO WO0149281A2
· 2001
[cited by applicant]
WO WO0294984A2
· 2002
[cited by applicant]
WO WO2005077899A2
· 2005
[cited by applicant]
WO WO2005097106A1
· 2005
[cited by applicant]
WO WO2006007310A2
· 2006
[cited by applicant]
WO WO2006127832A2
· 2006
[cited by applicant]
WO WO2007101247A2
· 2007
[cited by applicant]
WO WO2007127263A2
· 2007
[cited by applicant]
WO WO2008016554A1
· 2008
[cited by applicant]
WO WO2007133249A3
· 2009
[cited by applicant]
WO WO2009031023A2
· 2009
[cited by applicant]
WO WO2009120799A2
· 2009
[cited by applicant]
WO WO2009153652A2
· 2009
[cited by applicant]
WO WO2010118419A2
· 2010
[cited by applicant]
WO WO2011011721A2
· 2011
[cited by applicant]
WO WO2012088519A2
· 2012
[cited by applicant]
WO WO2012103487A1
· 2012
[cited by applicant]
WO WO2012113835A1
· 2012
[cited by applicant]
WO WO2014004902A2
· 2014
[cited by applicant]
WO WO2015100213A2
· 2015
[cited by applicant]
WO WO2017109195A1
· 2017
[cited by applicant]
WO WO2019168972A1
· 2019
[cited by applicant]
WO WO2021237214A1
· 2021
[cited by applicant]
WO WO2023031673A1
· 2023
[cited by applicant]
WO WO2023237926A2
· 2023
[cited by applicant]
WO WO2024246601A1
· 2024
[cited by applicant]
WO WO2024246603A1
· 2024
[cited by applicant]
WO WO2025078619A1
· 2025
[cited by applicant]
WO WO2025078645A1
· 2025
[cited by applicant]
Hu et al Laryngoscope, 2011, 121(5) 978-982 (Year: 2011).
[cited by examiner]
Bishayee Cancer. Prev. Res, 2009, 2(5) 409-418 (Year: 2009).
[cited by examiner]
Song et al Scientific Reports 2012 2:362 1-9 (Year: 2012).
[cited by examiner]
Bialonska et al J. Agric. Food Chem 2009, 57, 10181-10186 (Year: 2009).
[cited by examiner]
Eisenberg et al Nature Cell Biology, 2009, 11(11), 1305-1314 (Year: 2009).
[cited by examiner]
Chen et al Aging Cell, 2011, 10(5) 908-911; abstract (Year: 2011).
[cited by examiner]
Chen, T. et al., “Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells”, Aging Cell, 10(5):908-911 (Anatomical Society of Great Britain and Ireland, UK, Jun. 1…
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP Application No. 13735543.4 dated Dec. 14, 2020.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP Application No. 13735543.4 dated Dec. 20, 2017.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP Application No. 13735543.4 dated May 20, 2020.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP Application No. 13735543.4 dated May 27, 2019.
[cited by applicant]
Decision to Grant a European Patent Pursuant to Article 91(1) EPC for EP Application No. 13735543.4 dated Aug. 18, 2023.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US13/48310 dated Jan. 22, 2014.
[cited by applicant]
Kasimsetty, et al., “Colon cancer chemopreventive activities of pomegranate ellagitannins and Urolithins,” J Agric Food Chem, 58(4): 2180-2187 (2010).
[cited by applicant]
Kiss et al., “Epigenetic modulation of mechanisms involved in inflammation: Influence of selected polyphenolic substances on histone acetylation state”, Food Chemistry, 131(3):1015-1020 (Elsevier Ltd., Netherlands, Sep.…
[cited by applicant]
Landete, “Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health”, Food Research International, 44(5):1150-1160 (Elsevier Applied Science, Barking, GB, Apr. 17…
[cited by applicant]
Saul et al., “Diversity of Polyphenol Action in Caenohabditis elegans: Between Toxicity and Longevity”, Journal of Natural Products, 74(8):1713-1720 (American Chemical Society and American Society of Pharmacognosy, USA,…
[cited by applicant]
Adams et al., “Pomegranate Ellagitannin-Derived Compounds Exhibit Antiproliferative and Antiaromatase Activity in Breast Cancer Cells In Vitro,” Cancer Prev Res, 3: 108-113 (2010).
[cited by applicant]
Andreux et al., “Appendix A: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans,” Nature Metabolish, 1:595-603 (2019).
[cited by applicant]
Berry Health Benefits Symposium (2009 Berry Health Benefits Symposium).
[cited by applicant]
Bhattacharyya et al., “Beneficial Effect of Processed Shilajit on Swimming Exercise Induced Impaired Energy Status of Mice,” Pharmacologyonline, 1: 817-825 (2009).
[cited by applicant]
Bhattacharyya et al., “Shilajit Dibezno-alpha-Pyrones: Mitochondria Targeted Antioxidants,” Pharmacologyonline, 2: 690-698 (2009).
[cited by applicant]
Bialonska, et al., “Urolithins, Intestinal Microbial Metabolites of Pomegranate Ellagitannins, Exhibit Potent Antioxidant Activity in a Cell-Based Assay,” J Agric Food Chem, 57(21); 10181-10186, 2009.
[cited by applicant]
Cerda et al., “Repeated oral administration of high doses of the pomegranate ellagitannin punialagin to rats for 37 days is not toxic,” J. Agric. Food Chem., 51(11):3493-3501 (2003).
[cited by applicant]
Chen et al., “Coordination of Autophagy and the Proteasome in Resolving Endoplasmic Reticulum Stress,” Veterinary Pathology 48(1):245-253 (2011).
[cited by applicant]
Chen et al., “Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats,” American Journal of Physiology Endocrinology and Metabolism 301.5 (2011): E853-E863.
[cited by applicant]
De Meyer et al., “Autophagy in the cardiovascular system,” Biochimica et Biophysica Acta 1793: pp. 1485-1495 (2009).
[cited by applicant]
Du et al., “Starving Neurons Show Sex Difference in Autophagy,” The Journal of Biological Chemistry, 284(4): 2383-2396 (2009).
[cited by applicant]
Extended European Search Report for EP Application No. 23175506.7 dated Jan. 8, 2023.
[cited by applicant]
Friedman et al., “NSAIDs in Dermatologic Therapy: Review and Preview.” J Cutan Med Surg 2002, 6(5):449-59.
[cited by applicant]
Ghosal et al., “Effects of shilajit and its active constituents on learning and memory in rats,” Phytotherapy Res, 7(1): 29-34 (1993).
[cited by applicant]
Ghosal et al., “Shilajit. Part 4. Chemistry of Two Bioactive Benzopyrone Metabolites,” J Chem Research (S), 11: 350-351 (1989).
[cited by applicant]
Gimenez-Bastida et al., “Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-induced inflammation and associated molecular markers in human aortic endothelial cells,” Mol. Nutr…
[cited by applicant]
Gonzalez-Sarrias et al., “NF-?B-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts.” British Journal of Nutrition 2010, 104, 503-512.
[cited by applicant]
Gulcin et al., “Antioxidant and Antiradical Activities of L-carnitine,” Life Sciences, 78: 803-811 (2006).
[cited by applicant]
Hipkiss, “Aging, proteotoxicity, mitochondria, glycation, NAD+ and carnosine: possible inter-relationships and resolution of the oxygen paradox”, Frontiers in aging neuroscience: 10 (2010).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP24/80149 dated Jan. 29, 2025.
[cited by applicant]
Ishimoto H. et al., “In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A.” Bioorg Med Chem Lett, 21(19): 5901-5904 (2011).
[cited by applicant]
Johanningsmeier et al., “Pomegranate as a functional food and nutraceutical source,” Ann Rev Food Sci Technol, 2:181-201 (2010).
[cited by applicant]
Larrosa et al., “Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism”, Journal of Nutritional Biochemis…
[cited by applicant]
Lin et al., “Pharmacological Promotion of Autophagy Alleviates Steatosis and Injury in Alcoholic and Non-alcoholic Fatty Liver Conditions in Mice,” J Hepatol. May 2013; 58(5):993-999.
[cited by applicant]
Liu et al., “Appendix C: Impact of Urolithin A vs Placebo Supplementation on Muscle Endurance and Mitochondrial Health in the Elderly: A Randomized Clinical Trial,” Manuscript Draft.
[cited by applicant]
Liu et al., “Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy.” Pharmacological Research 161 (2020): 105263.
[cited by applicant]
Manach et al., “Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies 1-3,” Am. J. Clin. Nutr. 81 (suppl):230S-242S (2005).
[cited by applicant]
Markaki et al., “Modeling human diseases in Caenorhabditis elegans,” Biotechnol J, 5:1261-1276 (2010).
[cited by applicant]
Mingorance et al., “Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders,” Vascular Health and Risk Management, 7:169-176 (2011).
[cited by applicant]
Ndiaye et al., “The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges.” Arch Biochem Biophys 2011, 508(2) 164-170.
[cited by applicant]
Nolan et al., “Over-the-Counter Topical Skincare Products: A Review of the Literature.” Journal of Drugs in Dermatology, 2012, 11(2), 220-224.
[cited by applicant]
Percival, “Antioxidants,” Clinical Nurtition Insights, 1998.
[cited by applicant]
Ratnam et al., “The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats,” Journal of Nanoscience and Nanotechnology 9 (2009): 6741-6746.
[cited by applicant]
Reuter et al., “Carnitine and Acylcarnitines Pharmacokinetic, Pharmacological and Clinical Aspects,” Clin Pharmacokinet, 51 (9): 553-572 (2012).
[cited by applicant]
Rubinsztein et al., “Autophagy and aging”, Cell 146(5): 682-695 (2011).
[cited by applicant]
Search Report for GB Application No. 2316295.1 dated Apr. 18, 2024.
[cited by applicant]
Seeram et al., “Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland”, J. Agric. Food Chem., 55:7732-7737 (American Chemical Society, USA, 2007).
[cited by applicant]
Silverman et al., “Modeling molecular and cellular aspects of human disease using the nematode caenorhabditis elegans,” Pediatric Research, 65(1):10-18 (2009).
[cited by applicant]
Singh et al., “Appendix B: Urolithin A improves leg muscle strength, exercise performance and mitochondrial health in a proof-of-concept clinical trial in overweight adults,” Manuscript Draft.
[cited by applicant]
Stout et al., “Mitochondria's Role in Skin Ageing,” Biology, 8(29): 12 pages (2019).
[cited by applicant]
Uchida, “Pathologic Changes and Autophagy: New Insights for the Pathogenesis of Animal Diseases,” Veterinary Pathology 54(6):881-884 (2017).
[cited by applicant]
Verzelloni et al., “Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites.” Mol. Nutr. Food Res, 55(1):35-43 (2011).
[cited by applicant]
Wang et al., “Gut microbial transformation, a potential improving factor in the therapeutic activities of four groups of natural compounds isolated from herbal medicines.” Fitoterapia 138 (2019): 104293.
[cited by applicant]
Zenjun et al., “Distribution of Ellagic Acids in Plantae and Their Bioactivities,” Natural Product Research and Development, 22:519-524 and 540 (2010).
[cited by applicant]
NIH, “What Is Atherosclerosis?” NHLBI, National Institutes of Health (2016).
[cited by applicant]
Abstract of unexamined Japanese application No. JP2010-280627 published Dec. 16, 2010.
[cited by applicant]
Basu et al., “Pomegranate juice: A heart-healthy fruit juice,” Nutr Rev, 67(1): 49-56 (2009).
[cited by applicant]
Cerda et al., “Identification of Urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds,” J Agric Food Chem, 53(14): 5571-5576 (2005).
[cited by applicant]
Cerda et al., “Pomegranate juice supplementation in a chronic obstructive pulmonary disease: a 5-week, randomized, double-blind, placebo-controlled trial,” Eur J Clin Nutr, 60: 245-253 (2006).
[cited by applicant]
Chaudhary et al., “Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review,” Journal of Advanced Pharmacy Education & Research, 2(1):32-67 (2012).
[cited by applicant]
Curto et al., “Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors,” Biochem Pharmacol, 57:663-672 (1999).
[cited by applicant]
Dell'agli, et al., “Ellagitannins of fruit rind of pomegranate (
[cited by applicant]
Farris, “The anti-aging effects of niacinamide” Dermatology Times, [online] Oct. 14, 2015<https://www.dermatologytimes.com/view/anti-aging-effects-niacinamide>.
[cited by applicant]
Ertam et al., “Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open-label study,” Journal of Dermatology, 35: 570-574 (2008).
[cited by applicant]
Esmaillzadeh et al., “Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia,” J Med Food, 7(3): 305-308 (2004).
[cited by applicant]
Espín et al., “Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans,” J Agric Food Chem, 55(25): 10476-10485 (2007).
[cited by applicant]
Hartman et al., “Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease”, Neurobiology of Disease, 24(3):506-515 (Elsevier Inc., St. Louis, MO 2006).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US11/67229 dated Jul. 25, 2024.
[cited by applicant]
Larrosa et al., “Ellagitannins, ellagic acid and vascular health”, Molecular Aspects of Medicine, 31(6):513-539 (Pergamon Press, Oxford, Great Britain, Dec. 1, 2010).
[cited by applicant]
Lee et al., “b-Secretase (BACE1) Inhibitors from Sanguisorbae Radix”, Arch. Pharm. Res., 28(7):799-803 (Korea, 2005).
[cited by applicant]
Liu et al. “Antiaging effects of urolithin A on replicative senescent human skin fibroblasts”, Rejuvenation Research, 22(3): 191-200 (2019).
[cited by applicant]
Pandya et al., “Disorders of Hyperpigmentation,” New and Emerging Therapies, 18(1): 91-98 (2000).
[cited by applicant]
Park et al., “Micronization of arbutine using supercritical anti-solvent,” Korean Journal of Chemical Engineering, 25(3): 581-584 (2008).
[cited by applicant]
Partial European Search Report for European Application No. 17186188.3 dated Oct. 27, 2017.
[cited by applicant]
Paula's choice skincare, “Trehalose”, [online] https://www.paulaschoice.com/ingredients/ingredient-trehalose.html [Accessed Aug. 11, 2022].
[cited by applicant]
Rock et al., “Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities,” J Agric Food …
[cited by applicant]
Sumner et al., “Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease,” Am J Cardiol, 96(6): 810-814 (2005).
[cited by applicant]
Trombold et al., “Ellagitannin Consumption Improves Strength Recovery 2-3 d after Eccentric Exercise”, Medicine and Science in Sports and Exercise, 42:493-498 (American College of Sports Medicine, Mar. 2010).
[cited by applicant]
Viuda-Martos et al., “Pomegranate and its Many Functional Components as Related to Human Health: A Review”, Comprehensive Reviews in Food Science and Food Safety, 9(6):635-654 (Oct. 22, 2010).
[cited by applicant]
Wang et al., “Antimelanogenic Effect of Urolithin A and Urolithin B, the Colonie Metabolites of Ellagic Acid, in B16 Melanoma Cells” Journal of Agricultural and Food Chemistry, 65: 6870-6876 (2017).
[cited by applicant]
Brummer et al., “Particle Characterisation in Excipients, Drug Products and Drug Substances” Sgs Life Science Services, Issue 11: 6 pages (2008).
[cited by applicant]
IN Application No. 392/CHE/2004 a (DSM IP Assets BV [NL]), filed Apr. 28, 2004.
[cited by applicant]
Salminen et al., “Glycolysis links p53 function with NF-κB signaling: Impact on cancer and aging process.” Journal of Cellular Physiology 224.1 (2010): 1-6.
[cited by applicant]
Kadowaki et al., “Nutrient control of macroautophagy in mammalian cells.” Molecular Aspects of Medicine 27.5-6 (2006): 426-443.
[cited by applicant]
Kannappan et al., “Neuroprotection by spice-derived nutraceuticals: you are what you eat!.” Molecular Neurobiology 44(2) (2011): 142-159.
[cited by applicant]
Tarnopolsky, “The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies.” Advanced Drug Delivery Reviews 60.13-14 (2008): 1561-1567.
[cited by applicant]
Škrha et al., “Minutes of The 42nd General Assembly of the European Association for the Study of Diabetes.” Diabetologia 50 (2007): S1-S538.
[cited by applicant]
Li et al., “EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin- stimulated macrophages.” Biochemical Pharmacology 81(9) (2011): 1152-1163.
[cited by applicant]
Bonetto et al., “Are antioxidants useful for treating skeletal muscle atrophy ?. ” Free Radical Biology and Medicine 47 (2009): 906-916.
[cited by applicant]
Williams et al., “Flavonoids: antioxidants or signalling molecules?.” Free Radical Biology and Medicine 36 (2004): 838-849.
[cited by applicant]
Wang et al., “The mitophagy pathway and its implications in human diseases.” Signal Transduction and Targeted Therapy 8 (2023): 304.
[cited by applicant]
Extended European Search Report for EP Application No. 25157187.3 dated Aug. 5, 2025.
[cited by applicant]
Patel et al., “A review of the use of biotin for hair loss.” Skin Appendage Disorders 3 (2017): 166-169.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP25/065409 dated Jun. 3, 2025.
[cited by applicant]
Smit et al., “The hunt for natural skin whitening agents.” International Journal of Molecular Sciences 10(12), 5326-5349 (2009).
[cited by applicant]
Peirano et al., “Dermal penetration of creatine from a face-care formulation containing creatine, guarana and glycerol is linked to effective antiwrinkle and antisagging efficacy in male subjects.” Journal of Cosmetic D…
[cited by applicant]